In November last year, the House of Representatives Standing Committee on Health, Aged Care and Sport delivered its bipartisan report “The New Frontier: Delivering better health for all Australians” on the approval processes for new drugs and novel medical technologies in Australia.
Australian Health Journal spoke to some of the industry bodies who were part of the Inquiry, for their comments on the process, the report and hopes in the recommendations being implemented.
Professor John Zalcberg OAM Australian Clinical Trials Alliance (ACTA) Board Director & former ACTA Board Chair
Shanny Dyer, Chief Executive Officer, ARCS Australia
Leanne Wells, Chief Executive Officer, Consumers Health Forum of Australia
Liz de Somer, Chief Executive Officer Medicines Australia
Ian Burgess, Chief Executive Officer,
Medical Technology Association of Australia
Watch Season 5, Australian Health Journal Episode S5E1
-
Pharmacy led men’s urological health
Men’s urological needs refer to the medical and surgical conditions that affect the male urinary tract system and reproductive organs.
A urologist can address these concerns, however a pharmacy-led model of care developed by Brad Butt, called Mens Health Downunder has offered an alternative to certain urological needs of the male adult population over the past 10 years.
Australian Health Journal met with Brad to hear about his journey, Mens Health Downunder and the impact the pharmacy-led model of care has had on patient’s urological as well as mental health.
-
Growing impact of blood cancer on women
According to the Leukaemia Foundation, blood cancer is one of the most urgent and under-recognised women’s health issues in Australia, with three times more Australian women diagnosed with blood cancer than ovarian and cervical cancer combined (Source: AIHW, Cancer Data in Australia, 2024).
Blood cancer has also emerged as the second most common cancer diagnosed in Australian women overall – behind only breast cancer – and the leading cancer amongst girls and women under the age of 30 (Source: AIHW, Cancer Data in Australia, 2024).
-
CASE STUDY: Evolution in the medical device supply chain
For Cardinal Health, a global manufacturer and distributor of medical products, the process begins when products arrive in Australia and are cleared by customs before being stored at their Sydney warehouse. From here, they fulfil orders for various clients, including hospitals and wholesalers, supported by DHL’s logistics services.
